about
O-GlcNAcylation and Metabolic Reprograming in CancerTopoisomerase IIβ binding protein 1 c.*229C>T (rs115160714) gene polymorphism and endometrial cancer riskRate of positive urine culture and double-J catheters colonization on the basis of microorganism DNA analysis.Gene and protein expression of glucose transporter 1 and glucose transporter 3 in human laryngeal cancer-the relationship with regulatory hypoxia-inducible factor-1α expression, tumor invasiveness, and patient prognosis.Effect of metformin on apoptosis induction in ovarian cancer cells.Gene expression of O-GlcNAc cycling enzymes in human breast cancersExpression of GLUT1 and GLUT3 glucose transporters in endometrial and breast cancers.Expression of TopBP1 in hereditary breast cancerLoss of heterozygosity for chromosomal regions 15q14-21.1, 17q21.31, and 13q12.3-13.1 and its relevance for prostate cancer.Identification of the key pathway of oxazolinoanthracyclines mechanism of action in cells derived from human solid tumors.Gene and protein expression of O-GlcNAc-cycling enzymes in human laryngeal cancer.Metallothionein 2A core promoter region genetic polymorphism and its impact on the risk, tumor behavior, and recurrences of sinonasal inverted papilloma (Schneiderian papilloma)Metallothionein 2A genetic polymorphisms and risk of ductal breast cancerThe calpain system as a potential target for pelvic muscle reinforcement.HIF-1, GLUT1, endoglin, and BIRC5 expression in urine samples obtained from patients with bladder malignancies - after photodynamic diagnosis (PDD).Expression of CTLA-4 and Foxp3 in peripheral blood T cells of patients with squamous cell laryngeal carcinoma.Diagnostic impact of promoter methylation and E-cadherin gene and protein expression levels in laryngeal carcinoma.The potential role of O-GlcNAc modification in cancer epigenetics.Differential expression of ten-eleven translocation genes in endometrial cancers.Thio-sugar motif of functional CARB-pharmacophore for antineoplastic activity. Part 2.The c.*229C > T gene polymorphism in 3'UTR region of the topoisomerase IIβ binding protein 1 gene and LOH in BRCA1/2 regions and their effect on the risk and progression of human laryngeal carcinoma.Diagnostic value of DNA alteration: loss of heterozygosity or allelic imbalance-promising for molecular staging of prostate cancers.The effect of metallothionein 2A core promoter region single-nucleotide polymorphism on accumulation of toxic metals in sinonasal inverted papilloma tissues.The -5 A/G single-nucleotide polymorphism in the core promoter region of MT2A and its effect on allele-specific gene expression and Cd, Zn and Cu levels in laryngeal cancer.Metallothionein 2A genetic polymorphisms and risk of prostate cancer in a Polish population.TGFβ-pathway is down-regulated in a uterine carcinosarcoma: a case study.Expression of hypoxia inducible factor 1α and 2α and its association with vitamin C level in thyroid lesions.Effect of metallothionein 2A gene polymorphism on allele-specific gene expression and metal content in prostate cancer.Data on Single Nucleotide Polymorphism of DNA Repair Genes and Breast Cancer Risk from Poland.RAD51 genotype and triple-negative breast cancer (TNBC) risk in Polish women.Analysis of DNA Repair Genes Polymorphisms in Breast Cancer.Gene/protein expression of CAPN1/2-CAST system members is associated with ERK1/2 kinases activity as well as progression and clinical outcome in human laryngeal cancer.Genetic polymorphism of metallothionein 2A and risk of laryngeal cancer in a Polish population.The expression of TLR pathway molecules in peripheral blood mononuclear cells and their relationship with tumor invasion and cytokine secretion in laryngeal carcinoma.The c.469+46_56del mutation in the homeobox MSX1 gene--a novel risk factor in breast cancer?Polymorphisms of homologous recombination RAD51, RAD51B, XRCC2, and XRCC3 genes and the risk of prostate cancer.Fibroblast growth factor receptor 1 and 3 expression is associated with regulatory PI3K/AKT kinase activity, as well as invasion and prognosis, in human laryngeal cancer.Impact of OGT deregulation on EZH2 target genes FOXA1 and FOXC1 expression in breast cancer cells.Hyperglycemia-Associated Dysregulation of O-GlcNAcylation and HIF1A Reduces Anticancer Action of Metformin in Ovarian Cancer Cells (SKOV-3)The expression of SOCS1 and TLR4-NFkappaB pathway molecules in neoplastic cells as potential biomarker for the aggressive tumor phenotype in laryngeal carcinoma
P50
Q27027028-E8D284F6-AC02-43B8-8D59-7FDB3F2F6F42Q33775038-E18B33E7-3539-4C92-867A-C787D8D45B00Q33819959-055E3CE2-749D-474F-9F24-6AFA2A0268CCQ35596889-70E00FF6-7B34-4629-83C7-A7CB817F7ECCQ35761271-B24CAB94-1E8F-48B4-B31F-DE7B825459F8Q35809895-7635EC4E-5E4D-4974-980B-18ABF50301BEQ35928789-EBDB22F2-4CFE-46EF-9E36-8C350E084004Q35981641-613274D2-BF34-4DA5-9649-00913C8C84D2Q36118895-E6AC570A-4C34-4018-B4DE-36CCA1334FECQ36174296-C12DA49E-6AFE-4C29-8426-3815E8B482BCQ36214824-B004273D-637A-4C1D-AF22-7CD04EA6D327Q36352771-BD4CEC2F-DDC2-4CA6-8EE1-3D8B5B748D2AQ37535008-2E850C20-FBFC-40E7-97F3-F4FB11EF8A1CQ37579056-8388D2D3-E141-49B9-BA2F-459C2FD5A68BQ37579133-0EB04F44-B640-4BFD-B425-4B6E8E003C95Q37601910-7C1DB366-CADF-4B1D-8AD2-E2C9D3D81F0DQ37601968-732782FB-DCC0-4B8E-8901-BA9E3604D929Q38241688-CEDC73B4-54A6-46D1-9032-62F727BBFFC6Q38871612-4823266E-E4DD-44A5-989A-E546DFF2ADFCQ38932998-9B81BA14-1DBC-44DF-B0CF-93265A670848Q41184434-77D574B2-D7FC-456D-BAB6-E20469FBA29FQ41674949-4A3756A3-8F2A-4542-84FE-E3CA8CD38182Q42701960-219848D3-8ECB-4F1E-B386-7F88A841971EQ42704371-B673B3D0-51D5-4478-885C-C63419C35D34Q44686582-D371CE75-1227-4043-AFF7-89242E1234BFQ45917324-75755B25-902B-4470-B94A-B9181C7EA5C8Q46702112-5AE0C7B3-C2DB-481F-B190-1E203151C041Q46864234-EF44DD6A-45CC-4065-A85C-3BB3C31EA4ECQ47360892-02D7FDA1-F43C-4DD1-901A-5595EDC704E7Q51033904-161E69C7-2094-4DAD-A017-8685565A1B85Q51544638-3063DC3F-DC42-47FE-BFC5-314CCB351DDBQ51617592-0C88AAFD-9D46-40B8-930E-75F8AD37AF85Q54201489-0B1A1284-BD39-4D18-B489-B92BDD47AC4AQ54329666-3BEF98F4-0CC7-4A0E-B2F9-F269761FC7A9Q54419283-26FAAC23-7575-4BE2-B958-2B746AB489AFQ54877659-FFF37B99-FE71-4DD2-897F-860C11104F54Q54985778-C5C24BA4-8022-4293-8F16-D4D8492D24B1Q55131833-A17B5A0F-3232-4B38-BC6E-F599EF0F0FD9Q58742476-964D3338-47DB-498C-807D-3A6BB54C4623Q82938609-E8665813-F235-4767-A2B5-46CAFB6B3031
P50
description
hulumtuese
@sq
polska biolog i biochemik
@pl
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Ewa Forma
@ast
Ewa Forma
@en
Ewa Forma
@es
Ewa Forma
@nl
Ewa Forma
@pl
type
label
Ewa Forma
@ast
Ewa Forma
@en
Ewa Forma
@es
Ewa Forma
@nl
Ewa Forma
@pl
prefLabel
Ewa Forma
@ast
Ewa Forma
@en
Ewa Forma
@es
Ewa Forma
@nl
Ewa Forma
@pl
P106
P1153
25929834600
P1559
Ewa Forma
@pl
P21
P214
5656147270701235700008
P31
P3124
P496
0000-0003-0230-6831
P735
P7859
viaf-5656147270701235700008